We are live on
!
Find out more
FO
FT Options Portfolio holdings
AUM
$66.4M
1-Year Est. Return
18.48%
This Fund
S&P 500
This Quarter
Est. Return
+24.92%
1 Year Est. Return
+18.48%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$126M
AUM Growth
+$9.73M
(+8.4%)
Cap. Flow
+$224M
Cap. Flow
% of AUM
177.31%
Top 10 Holdings %
Top 10 Hldgs %
37.67%
Holding
493
New
153
Increased
113
Reduced
67
Closed
127
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Procter & Gamble
PG
|
+$3.82M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$2.47M |
| 3 |
iShares Biotechnology ETF
IBB
|
+$2M |
| 4 |
Ulta Beauty
ULTA
|
+$1.86M |
| 5 |
MON
Monsanto Co
MON
|
+$1.82M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MDVN
MEDIVATION, INC.
MDVN
|
+$7.18M |
| 2 |
Biogen
BIIB
|
+$4.33M |
| 3 |
Cal-Maine
CALM
|
+$3.64M |
| 4 |
Apple
AAPL
|
+$2.74M |
| 5 |
ALR
Alere Inc
ALR
|
+$2.22M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 39.95% |
| 2 | Consumer Staples | 5.72% |
| 3 | Consumer Discretionary | 5.14% |
| 4 | Technology | 3.35% |
| 5 | Materials | 2.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MON
126
PUT
DELISTED
Monsanto Co
MON
| $147K | 0.12% |
+37,000
| New | +$3.88M |
|
127
Western Digital
WDC
$164B
| $146K | 0.12% |
3,301
-4,108
| -55% | -$155K |
|
128
CALL
Conagra Brands
CAG
$6.83B
| $145K | 0.11% |
+95,347
| New | +$3.42M |
|
|
CAB
129
CALL
DELISTED
Cabela's Inc
CAB
| $144K | 0.11% |
27,200
+11,100
| +69% | +$568K |
|
130
CALL
PepsiCo
PEP
$187B
| $141K | 0.11% |
208,000
+43,000
| +26% | +$4.63M |
|
|
ENDP
131
DELISTED
Endo International plc
ENDP
| $137K | 0.11% |
6,800
-13,500
| -67% | -$268K |
|
|
XLNX
132
CALL
DELISTED
Xilinx Inc
XLNX
| $137K | 0.11% |
95,100
+38,700
| +69% | +$1.99M |
|
133
CALL
Deere & Co
DE
$161B
| $136K | 0.11% |
+50,000
| New | +$4.09M |
|
134
CALL
State Street SPDR S&P 500 ETF Trust
SPY
$774B
| $136K | 0.11% |
71,500
-222,500
| -76% | -$48.1M |
|
135
PUT
Adobe
ADBE
$94.3B
| $133K | 0.11% |
34,900
+4,900
| +16% | +$492K |
|
136
PUT
Exelixis
EXEL
$14.1B
| $133K | 0.11% |
+104,700
| New | +$1.13M |
|
137
Best Buy
BBY
$18B
| $132K | 0.1% |
+3,454
| New | +$121K |
|
|
138
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$774B
| $132K | 0.1% |
52,500
+45,500
| +650% | +$9.83M |
|
139
CALL
Take-Two Interactive
TTWO
$43.9B
| $130K | 0.1% |
+78,000
| New | +$3.29M |
|
140
Molson Coors Class B
TAP
$7.68B
| $129K | 0.1% |
+1,176
| New | +$120K |
|
|
FLNA
141
PUT
Filana Therapeutics
FLNA
$51.2M
| $128K | 0.1% |
12,429
+1,715
| +16% | +$28.4K |
|
142
PUT
Microsoft
MSFT
$2.93T
| $125K | 0.1% |
71,200
+34,800
| +96% | +$1.96M |
|
|
TWTR
143
CALL
DELISTED
Twitter, Inc.
TWTR
| $122K | 0.1% |
+80,000
| New | +$1.51M |
|
|
CSOD
144
CALL
DELISTED
Cornerstone OnDemand, Inc.
CSOD
| $120K | 0.1% |
+40,200
| New | +$1.76M |
|
|
HZNP
145
CALL
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $120K | 0.1% |
+40,000
| New | +$781K |
|
146
CALL
Coca-Cola Europacific Partners
CCEP
$46.5B
| $117K | 0.09% |
64,200
+44,800
| +231% | +$1.71M |
|
|
147
CALL
Procter & Gamble
PG
$349B
| $115K | 0.09% |
16,000
| – | – |
|
148
CALL
IBM
IBM
$200B
| $113K | 0.09% |
15,062
+1,987
| +15% | +$302K |
|
149
PUT
Oracle
ORCL
$364B
| $113K | 0.09% |
42,800
+12,800
| +43% | +$522K |
|
150
Alaunos Therapeutics
TCRT
$5.01M
| $113K | 0.09% |
133
-67
| -34% | -$53.9K |
|
Similar funds
MC
FIM
TLIC
MKCM
ACM
MFM
VE
GFWEV
FT Options's Q3 2016 Portfolio in Review
As of Q3 2016, FT Options held 493 positions worth $126M, up 8.4% from $116M the previous quarter. Its ten largest holdings account for 38% of the portfolio.
FT Options deployed $224M of net new capital in Q3 2016, opening 153 new positions and adding to 113 existing holdings. Its largest new stake was iShares Biotechnology ETF: 21,000 shares worth $2.03M.
By sector, the portfolio is most concentrated in Healthcare at 40% of assets, down from 41% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.
On the sell side, the largest reduction was Apple, an estimated $2.74M trimmed.
- FT Options's largest Q3 2016 buy was iShares Biotechnology ETF: 21,000 shares worth $2.03M.
- FT Options added most to Procter & Gamble in Q3 2016, an estimated $3.82M increase.
- FT Options's biggest Q3 2016 reduction was Apple, cutting an estimated $2.74M.
- FT Options fully exited MEDIVATION, INC. in Q3 2016, selling an estimated $7.18M.
- FT Options's ten largest holdings make up 38% of its $126M portfolio in Q3 2016.
- FT Options opened 153 new positions and closed 127 in Q3 2016.
- FT Options's portfolio value rose 8.4% quarter-over-quarter to $126M.
Based on FT Options's 13F filing for Q3 2016, filed 10 Nov 2016.